Chronic Kidney Disease News

In October 2023, the American Heart Association unveiled the term cardiovascular-kidney-metabolic syndrome to reflect the connection between metabolic and renal conditions associated with risk for heart disease.

Urinary plasminogen and the ratio of measured to expected plasminogen may be independently linked to the risk of progression to end-stage kidney disease, data show.

Patients with end-stage kidney disease may be at higher risk for hypoglycemia, with a disproportionate effect on young, Black and female patients, according to published data.

Ardelyx Inc. is leading a lawsuit against CMS about plans by the agency to include oral-only phosphate-lowering therapies into the End-Stage Renal Disease Prospective Payment System by January 2025.

Primary care providers play a critical role in detecting and managing cardiovascular-kidney-metabolic syndrome, according to experts.

Socioeconomic status may play a role in the health outcomes of children and adolescents with chronic kidney disease, according to a published review of current evidence.

A text message-based survey was highly acceptable and had moderate reach for patients on dialysis, according to published data, though response rates were lower in certain groups.

A new drug application for sotagliflozin as an adjunct to insulin therapy for adults with type 1 diabetes and chronic kidney disease has been resubmitted to the FDA, according to a press release.

Dietary patterns may vary significantly in patients with different stages of chronic kidney disease, according to an investigation of food group intake among patients in a United Kingdom study.

Combined SGLT2 inhibitor and GLP-1 receptor agonist therapy could provide additional cardiovascular and renal benefits for adults with type 2 diabetes, according to data from a meta-analysis published in The Lancet Diabetes & Endocrinology.